Persistence and Activity of Allogeneic Vγ9Vδ2 T Cells Following Adoptive Transfer
toxicities
Patients surviving beyond 28 days were re-dosed without further lymphodepletion. In 3 patients who had CR (5007), MLFS or SD (5002, 5006) at the day 28 assessment, the protocol criteria were met for redosing with dosing based on the advice of the trial steering committee. No dose limiting toxicities were documented following repeat infusion. In patient 5002, initial infusion with the lowest dose of 1 × 10Clinical response and Vg9d2 T cell persistence in blood in patients PRA1-5006 (A) and PRA1-5007 (B). Bone marrow (BM) blast % (i) and neutrophil counts (ii) were performed at the clinical site at various time points. Graphs presented in i and ii are extrapolations from clinical data generated at the clinical site. For patient PRA1-5006, MRD (dark red symbols, A, i) was monitored by measuring RUNX1-RUNX1T1 transcript levels arising from t (8;21) by real-time qPCR. Proportional contribution (%) of Product/Donor to Vγ9δ2 T cell (iii) in patient blood samples (taken at the clinical site) was assessed by flow cytometry at TC BioPharm for research purposes only, utilizing the partial Product/Patient HLA mismatch (iv). Black arrows with i, ii, and iii indicate time of first, second, and third dose, respectively.